The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment
| Autor: | Ana Paula Comarella, Danilo Vilagellin, Natassia Elena Bufalo, Jessica Ferreira Euflauzino, Elisangela de Souza Teixeira, Ana Beatriz Pinotti Pedro Miklos, Roberto Bernardo dos Santos, João H. Romaldini, Laura S. Ward |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Archives of Endocrinology and Metabolism, Vol 64, Iss 6, Pp 787-795 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2359-4292 2359-3997 |
| DOI: | 10.20945/2359-3997000000295 |
| Popis: | ABSTRACT Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves’ disease patients, mainly for controlling body weight following treatment. Subjects and methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306). Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|